目的:探讨有4个跨膜区的L6超家族成员1(transmembrane 4Lsix family member 1,TM4SF1)基因在上皮性卵巢癌(卵巢癌)组织中的表达及其临床价值。方法:用RT-PCR法检测TM4SF1基因在36例卵巢癌、15例卵巢良性肿瘤、13例正常卵巢组织中的表达...目的:探讨有4个跨膜区的L6超家族成员1(transmembrane 4Lsix family member 1,TM4SF1)基因在上皮性卵巢癌(卵巢癌)组织中的表达及其临床价值。方法:用RT-PCR法检测TM4SF1基因在36例卵巢癌、15例卵巢良性肿瘤、13例正常卵巢组织中的表达。结果:TM4SF1基因在卵巢癌中表达为(0.173±0.054)、良性肿瘤为(0.134±0.015)、正常卵巢组织为(0.118±0.008)。癌组织中的表达水平高于卵巢良性肿瘤(P=0.031);癌组织中的表达水平高于正常卵巢组织(P=0.004);良性卵巢肿瘤组织中的表达水平高于正常卵巢组织(P=0.012);手术—病理分期为Ⅰ-Ⅱ期癌组织中的表达水平(0.124±0.02)低于Ⅲ期(0.164±0.024)(P<0.05);高分化癌组织中的表达水平为(0.091±0.052),中—低分化癌组织表达为(0.113±0.024)(P>0.05)。结论:TM4SF1基因的表达与卵巢癌相关,可能在卵巢癌的发生、发展过程中起一定作用。展开更多
目的 探讨跨膜四超家族成员1（transmembrane 4 super family 1，TM4SF1）蛋白在人卵巢组织中的表达及其与上皮性卵巢癌临床病理因素的关系。方法 采用免疫组化SP法检测16例正常卵巢上皮组织、23例上皮性卵巢良性肿瘤组织及55例上皮性...目的 探讨跨膜四超家族成员1（transmembrane 4 super family 1，TM4SF1）蛋白在人卵巢组织中的表达及其与上皮性卵巢癌临床病理因素的关系。方法 采用免疫组化SP法检测16例正常卵巢上皮组织、23例上皮性卵巢良性肿瘤组织及55例上皮性卵巢癌癌组织中TM4SF1蛋白的表达情况，分析其与上皮性卵巢癌临床病理因素及预后的关系。结果 ①TM4SF1蛋白在上皮性卵巢癌癌组织中的阳性表达率（90.90%）高于上皮性卵巢良性肿瘤组织（65.22%）及正常卵巢上皮组织（25.00%）的阳性表达率，差异有统计学意义（P〈0.05）。②TM4SF1蛋白在正常卵巢上皮细胞中的表达主要位于上皮细胞的细胞膜和细胞膜近基底膜处及细胞质中，在卵巢良性肿瘤组织中的表达主要集中在肿瘤细胞的细胞膜近基底膜处及细胞膜其他部位，而在卵巢癌细胞中则主要分布于癌细胞的细胞质中。③Ⅲ～Ⅳ期卵巢癌患者TM4SF1蛋白的阳性表达率高于Ⅰ～Ⅱ期患者，中低分化癌患者TM4SF1蛋白的阳性表达率高于高分化癌患者（P〈0.05）。④TM4SF1蛋白的阳性表达率与组织学类型、腹水量的多少无明显相关（P〉0.05），而与FIGO分期及组织学分级明显相关（P〈0.05）。⑤Cox比例风险回归模型多因素分析显示TM4SF1蛋白在卵巢癌癌组织中的阳性表达不是影响患者生存的独立预后因素。结论 TM4SF1蛋白在上皮性卵巢癌癌组织中呈高表达，可能与卵巢癌的发生、发展相关。展开更多
目的预测并筛选免疫反应性较强的四跨膜蛋白超家族成员1(transmembrane 4 L6 family member 1,TM4SF1)人类白细胞抗原A2(human leukocyte antigen A2,HLA-A2)限制性T淋巴细胞(cytotoxic lymphocyte,CTL)表位肽。方法联合4种软件(BIMAS、...目的预测并筛选免疫反应性较强的四跨膜蛋白超家族成员1(transmembrane 4 L6 family member 1,TM4SF1)人类白细胞抗原A2(human leukocyte antigen A2,HLA-A2)限制性T淋巴细胞(cytotoxic lymphocyte,CTL)表位肽。方法联合4种软件(BIMAS、SYFPEITHI、IEDB、PROPRED I)对TM4SF1的HLA-A2限制性CTL表位进行预测,并采用预培养法酶联免疫斑点法(enzyme-linked immunospot assy,ELISOPT)、直接法ELISOPT对所测得表位肽的免疫反应性进行鉴定。结果 4种不同软件共预测出10条表位多肽,对其中4条(P1、P2、P8、P10)进行免疫反应性验证。多肽活化CTL能力结果显示,预培养法ELISPOT产生斑点形成细胞(spvt forming cell,SFC)的净值T明显高于直接法ELISPOT:[(阳性对照肽:322±8 vs 169±22,P<0.05)、(多肽P1:114±10 vs 39±7,P<0.05)、(多肽P10:156±31 vs 52±8,P<0.05)]。单个活化CTL细胞分泌INF-γ因子的水平检测结果显示,预培养法ELISPOT产生斑点的平均大小明显大于直接法ELISPOT[(阳性对照肽:21.91±2.45 vs 13.80±1.76,P<0.05)、(多肽P1:12.90±0.88 vs 8.31±1.40,P<0.05)、(多肽P10:17.50±3.85 vs 11.96±0.61,P<0.05)]。表位多肽P1、P10均具有免疫原性,P10的免疫活性更高。结论预培养法ELISPOT检测多肽的免疫反应性较直接法ELISPOT灵敏性更高,多种软件联合ELISPOT预培养法可有效筛选出免疫反应性更强的卵巢癌相关抗原TM4SF1 HLA-A2限制性CTL优势表位,其中P10的免疫活性最高。展开更多
目的探讨血清癌胚抗原相关细胞粘附分子1(carcino-embryonic antigen related cellular adhesion molecule 1,CEACAM1)、四次跨膜蛋白1(transmembrane 4 L six family member 1,TM4SF1)在乳腺癌组织中的表达及诊断价值。方法收集乳腺癌9...目的探讨血清癌胚抗原相关细胞粘附分子1(carcino-embryonic antigen related cellular adhesion molecule 1,CEACAM1)、四次跨膜蛋白1(transmembrane 4 L six family member 1,TM4SF1)在乳腺癌组织中的表达及诊断价值。方法收集乳腺癌96例。采用酶联免疫吸附试验检测血清CEACAM1、TM4SF1水平。统计血清CEACAM1、TM4SF1水平与临床病理参数的关系及诊断效能。结果乳腺癌血清CEACAM1、TM4SF1水平与患者年龄、肿瘤直径、病理类型、雌激素受体、孕激素受体均无关,P>0.05,与病理分化程度、TNM分期、转移情况均有关。血清CEACAM1、TM4SF1水平联合诊断效能均较单一诊断效能高,P<0.05。结论血清CEACAM1、TM4SF1水平与乳腺癌病理分化程度、TNM分期、转移情况均有关,可作为肿瘤诊断标志物,联合诊断效能更高。展开更多
目的利用生物信息学方法分析四次跨膜蛋白L6家族成员1(Transmembrane-4 L-six family member-1,TM4SF1)在结直肠癌组织中表达的情况,并探究TM4SF1对结直肠癌增殖、迁移及凋亡的影响。方法通过癌症基因组图谱(The Cancer Genome Atlas,TC...目的利用生物信息学方法分析四次跨膜蛋白L6家族成员1(Transmembrane-4 L-six family member-1,TM4SF1)在结直肠癌组织中表达的情况,并探究TM4SF1对结直肠癌增殖、迁移及凋亡的影响。方法通过癌症基因组图谱(The Cancer Genome Atlas,TCGA)数据库利用生物信息学方法分析TM4SF1在结直肠癌组织和正常组织中表达情况。qRT-PCR方法检测TM4SF1 mRNA在结直肠癌细胞中表达情况。构建下调TM4SF1的结直肠癌细胞株,分为三组进行研究,包括对照组(未做任何处理的细胞)、NC组(加入空载质粒载体)、si-TM4SF1组(加入TM4SF1-siRNA质粒),应用实时荧光定量PCR(Real-time PCR,qRT-PCR),验证转染效率;采用CCK-8实验观察各组细胞在48 h的增殖情况;采用Transwell实验检测各组细胞迁移能力;采用流式细胞术检测各组细胞凋亡情况。结果TCGA数据库分析结果显示与正常结直肠组织相比TM4SF1 mRNA在结直肠癌组织中表达增高(P<0.01)。qRT-PCR检测结果显示,与对照组、NC组相比,si-TM4SF1组中TM4SF1 mRNA表达量明显降低(P<0.01);同时,CCK-8实验结果显示,与对照组、NC组相比,si-TM4SF1组中SW1116细胞增殖能力明显降低(P<0.01);Transwell实验结果表明,si-TM4SF1组中SW1116细胞迁移能力与对照组、NC组相比明显降低(P<0.01);流式细胞术结果显示,与对照组、NC组相比,si-TM4SF1组中SW1116细胞凋亡明显增加(P<0.01)。结论下调TM4SF1可以抑制结直肠癌SW1116细胞的增殖、迁移能力,促进结直肠癌细胞凋亡。展开更多
Objective Accumulating evidence suggests that transmembrane 4 L6 family member 1(TM4SF1)is associated with the development of various cancers;yet comprehensive studies on TM4SF1 in cervical cancer are lacking.Therefor...Objective Accumulating evidence suggests that transmembrane 4 L6 family member 1(TM4SF1)is associated with the development of various cancers;yet comprehensive studies on TM4SF1 in cervical cancer are lacking.Therefore,we aimed to evaluate the prognostic value of TM4SF1 in cervical cancer,elucidate its potential oncogenic functions in this disease,and further explore its feasibility as a therapeutic target.Methods The expression profiles and clinical information of cervical cancer patients were obtained from The Cancer Genome Atlas(TCGA)database.The expression levels of TM4SF1 were compared between cervical cancer and normal cervical tissues using the Wilcoxon rank-sum test.Kaplan–Meier analysis was employed to assess the prognostic value of TM4SF1.Furthermore,functional enrichment analyses were performed to explore the associated signaling pathways and biological functions.The methylation status of TM4SF1 was analyzed using the UALCAN and MethSurv databases.In addition,in vitro experiments were conducted to preliminarily validate the role and mechanisms of TM4SF1 in cervical cancer.Results TM4SF1 was overexpressed in nearly all tumors,and its overexpression was associated with poor prognosis in cervical cancer.Moreover,the correlation between TM4SF1 expression and the expression of immune cell infiltration markers and immune checkpoint genes suggested that it had potential applications in cancer immunotherapy.Western blot analysis and immunohistochemistry revealed significantly elevated protein levels of TM4SF1 in cervical cancer tissues and cells.Further studies revealed that the knockdown of TM4SF1 significantly inhibited the migration,invasion,and epithelial-mesenchymal transition(EMT)of HeLa and SiHa cells,as well as promoted their apoptosis.Conclusion TM4SF1 may serve as a potential prognostic biomarker and therapeutic target for cervical cancer.展开更多
文摘目的:探讨有4个跨膜区的L6超家族成员1(transmembrane 4Lsix family member 1,TM4SF1)基因在上皮性卵巢癌(卵巢癌)组织中的表达及其临床价值。方法:用RT-PCR法检测TM4SF1基因在36例卵巢癌、15例卵巢良性肿瘤、13例正常卵巢组织中的表达。结果:TM4SF1基因在卵巢癌中表达为(0.173±0.054)、良性肿瘤为(0.134±0.015)、正常卵巢组织为(0.118±0.008)。癌组织中的表达水平高于卵巢良性肿瘤(P=0.031);癌组织中的表达水平高于正常卵巢组织(P=0.004);良性卵巢肿瘤组织中的表达水平高于正常卵巢组织(P=0.012);手术—病理分期为Ⅰ-Ⅱ期癌组织中的表达水平(0.124±0.02)低于Ⅲ期(0.164±0.024)(P<0.05);高分化癌组织中的表达水平为(0.091±0.052),中—低分化癌组织表达为(0.113±0.024)(P>0.05)。结论:TM4SF1基因的表达与卵巢癌相关,可能在卵巢癌的发生、发展过程中起一定作用。
文摘目的 探讨跨膜四超家族成员1（transmembrane 4 super family 1，TM4SF1）蛋白在人卵巢组织中的表达及其与上皮性卵巢癌临床病理因素的关系。方法 采用免疫组化SP法检测16例正常卵巢上皮组织、23例上皮性卵巢良性肿瘤组织及55例上皮性卵巢癌癌组织中TM4SF1蛋白的表达情况，分析其与上皮性卵巢癌临床病理因素及预后的关系。结果 ①TM4SF1蛋白在上皮性卵巢癌癌组织中的阳性表达率（90.90%）高于上皮性卵巢良性肿瘤组织（65.22%）及正常卵巢上皮组织（25.00%）的阳性表达率，差异有统计学意义（P〈0.05）。②TM4SF1蛋白在正常卵巢上皮细胞中的表达主要位于上皮细胞的细胞膜和细胞膜近基底膜处及细胞质中，在卵巢良性肿瘤组织中的表达主要集中在肿瘤细胞的细胞膜近基底膜处及细胞膜其他部位，而在卵巢癌细胞中则主要分布于癌细胞的细胞质中。③Ⅲ～Ⅳ期卵巢癌患者TM4SF1蛋白的阳性表达率高于Ⅰ～Ⅱ期患者，中低分化癌患者TM4SF1蛋白的阳性表达率高于高分化癌患者（P〈0.05）。④TM4SF1蛋白的阳性表达率与组织学类型、腹水量的多少无明显相关（P〉0.05），而与FIGO分期及组织学分级明显相关（P〈0.05）。⑤Cox比例风险回归模型多因素分析显示TM4SF1蛋白在卵巢癌癌组织中的阳性表达不是影响患者生存的独立预后因素。结论 TM4SF1蛋白在上皮性卵巢癌癌组织中呈高表达，可能与卵巢癌的发生、发展相关。
文摘目的预测并筛选免疫反应性较强的四跨膜蛋白超家族成员1(transmembrane 4 L6 family member 1,TM4SF1)人类白细胞抗原A2(human leukocyte antigen A2,HLA-A2)限制性T淋巴细胞(cytotoxic lymphocyte,CTL)表位肽。方法联合4种软件(BIMAS、SYFPEITHI、IEDB、PROPRED I)对TM4SF1的HLA-A2限制性CTL表位进行预测,并采用预培养法酶联免疫斑点法(enzyme-linked immunospot assy,ELISOPT)、直接法ELISOPT对所测得表位肽的免疫反应性进行鉴定。结果 4种不同软件共预测出10条表位多肽,对其中4条(P1、P2、P8、P10)进行免疫反应性验证。多肽活化CTL能力结果显示,预培养法ELISPOT产生斑点形成细胞(spvt forming cell,SFC)的净值T明显高于直接法ELISPOT:[(阳性对照肽:322±8 vs 169±22,P<0.05)、(多肽P1:114±10 vs 39±7,P<0.05)、(多肽P10:156±31 vs 52±8,P<0.05)]。单个活化CTL细胞分泌INF-γ因子的水平检测结果显示,预培养法ELISPOT产生斑点的平均大小明显大于直接法ELISPOT[(阳性对照肽:21.91±2.45 vs 13.80±1.76,P<0.05)、(多肽P1:12.90±0.88 vs 8.31±1.40,P<0.05)、(多肽P10:17.50±3.85 vs 11.96±0.61,P<0.05)]。表位多肽P1、P10均具有免疫原性,P10的免疫活性更高。结论预培养法ELISPOT检测多肽的免疫反应性较直接法ELISPOT灵敏性更高,多种软件联合ELISPOT预培养法可有效筛选出免疫反应性更强的卵巢癌相关抗原TM4SF1 HLA-A2限制性CTL优势表位,其中P10的免疫活性最高。
文摘目的探讨血清癌胚抗原相关细胞粘附分子1(carcino-embryonic antigen related cellular adhesion molecule 1,CEACAM1)、四次跨膜蛋白1(transmembrane 4 L six family member 1,TM4SF1)在乳腺癌组织中的表达及诊断价值。方法收集乳腺癌96例。采用酶联免疫吸附试验检测血清CEACAM1、TM4SF1水平。统计血清CEACAM1、TM4SF1水平与临床病理参数的关系及诊断效能。结果乳腺癌血清CEACAM1、TM4SF1水平与患者年龄、肿瘤直径、病理类型、雌激素受体、孕激素受体均无关,P>0.05,与病理分化程度、TNM分期、转移情况均有关。血清CEACAM1、TM4SF1水平联合诊断效能均较单一诊断效能高,P<0.05。结论血清CEACAM1、TM4SF1水平与乳腺癌病理分化程度、TNM分期、转移情况均有关,可作为肿瘤诊断标志物,联合诊断效能更高。
基金the Natural Science Fund of Hubei Province(No.2022CFC019 and No.2021CFB430).
文摘Objective Accumulating evidence suggests that transmembrane 4 L6 family member 1(TM4SF1)is associated with the development of various cancers;yet comprehensive studies on TM4SF1 in cervical cancer are lacking.Therefore,we aimed to evaluate the prognostic value of TM4SF1 in cervical cancer,elucidate its potential oncogenic functions in this disease,and further explore its feasibility as a therapeutic target.Methods The expression profiles and clinical information of cervical cancer patients were obtained from The Cancer Genome Atlas(TCGA)database.The expression levels of TM4SF1 were compared between cervical cancer and normal cervical tissues using the Wilcoxon rank-sum test.Kaplan–Meier analysis was employed to assess the prognostic value of TM4SF1.Furthermore,functional enrichment analyses were performed to explore the associated signaling pathways and biological functions.The methylation status of TM4SF1 was analyzed using the UALCAN and MethSurv databases.In addition,in vitro experiments were conducted to preliminarily validate the role and mechanisms of TM4SF1 in cervical cancer.Results TM4SF1 was overexpressed in nearly all tumors,and its overexpression was associated with poor prognosis in cervical cancer.Moreover,the correlation between TM4SF1 expression and the expression of immune cell infiltration markers and immune checkpoint genes suggested that it had potential applications in cancer immunotherapy.Western blot analysis and immunohistochemistry revealed significantly elevated protein levels of TM4SF1 in cervical cancer tissues and cells.Further studies revealed that the knockdown of TM4SF1 significantly inhibited the migration,invasion,and epithelial-mesenchymal transition(EMT)of HeLa and SiHa cells,as well as promoted their apoptosis.Conclusion TM4SF1 may serve as a potential prognostic biomarker and therapeutic target for cervical cancer.
